description
Helex has developed a proprietary lipid nanoparticle (LNP) delivery system that delivers gene-editing therapies directly to kidney cells, solving one of gene therapy's toughest challenges. Their lead program targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), a genetic kidney disorder affecting 12 million people worldwide with no curative treatment available.
founders
Poulami Chaudhuri
Rohini Kalvakuntla
Anirudh Nishtala
founded
2021
year of investment
Oct 2025
"
why we invested
ADPKD represents a significant unmet medical need, with current treatments limited to symptom management and not effective for all patients. Helex’s first-in-class mechanism of action has the potential to be a curative therapy and positions the company to build a differentiated pipeline of therapies for genetic kidney diseases.
